AbbVie Inc

Market Summary

USD149.23+1.26

Market Closed

0.85%

ABBV Alerts

Big fall in earnings (Y/Y)

ABBV Stock Price

View Fullscreen

ABBV RSI Chart

ABBV Alerts

Big fall in earnings (Y/Y)

ABBV Valuation

Market Cap

263.7B

Price/Earnings (Trailing)

40.48

Price/Sales (Trailing)

4.78

EV/EBITDA

34.92

Price/Free Cashflow

10.66

ABBV Price/Sales (Trailing)

ABBV Profitability

EBT Margin

14.51%

Return on Equity

53.71%

Return on Assets

4.78%

Free Cashflow Yield

9.38%

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

55.1B

Revenue Y/Y

-5.97%

Revenue Q/Q

0.45%

ABBV Earnings

Earnings (TTM)

6.5B

Earnings Y/Y

-54.98%

Earnings Q/Q

-12.15%

Price Action

Last 7 days

4.1%

Last 30 days

5.1%

Last 90 days

0.1%

Trailing 12 Months

-10.1%

How does ABBV drawdown profile look like?

ABBV Financial Health

Current Ratio

0.96

Debt/Equity

4.59

Debt/Cashflow

0.46

ABBV Investor Care

Buy Backs (1Y)

0.17%

Diluted EPS (TTM)

3.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	56.7B	56.0B	55.1B	0
2022	56.7B	57.3B	57.8B	58.1B
2021	50.2B	53.7B	55.2B	56.2B
2020	34.1B	36.2B	40.6B	45.8B
2019	32.6B	32.6B	32.9B	33.3B
2018	29.6B	30.9B	32.2B	32.8B
2017	26.2B	26.7B	27.3B	28.2B
2016	23.8B	24.8B	25.2B	25.6B
2015	20.4B	21.0B	21.9B	22.9B
2014	19.0B	19.3B	19.6B	20.0B
2013	18.5B	18.7B	18.9B	18.8B
2012	17.7B	17.9B	18.1B	18.4B
2011	16.1B	16.5B	17.0B	17.4B
2010	0	0	0	15.6B

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for ABBV

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 25, 2023	gonzalez richard a	gifted	-	-	-42,000	chairman of the board and ceo
Sep 07, 2023	alpern robert j	acquired	-	-	129	-
Aug 01, 2023	gonzalez richard a	sold	-8,914,800	148	-60,000	chairman of the board and ceo
Jul 31, 2023	gonzalez richard a	sold	-2,759,280	149	-18,500	chairman of the board and ceo
May 11, 2023	strom carrie c	sold (taxes)	-421,104	146	-2,876	svp & pres global allerg aesth
May 05, 2023	burnside william h.l.	acquired	-	-	1,450	-
May 05, 2023	austin roxanne s	acquired	-	-	1,450	-
May 05, 2023	alpern robert j	acquired	-	-	1,450	-
May 05, 2023	freyman thomas c	acquired	-	-	1,450	-
May 05, 2023	roberts rebecca b	acquired	-	-	1,450	-

Which funds bought or sold ABBV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 07, 2023	DAGCO, INC.	added	0.08	121,925	1,258,060	0.65%
Dec 07, 2023	Financial Advisory Group	unchanged	-	60,874	633,207	0.13%
Dec 07, 2023	Hudson Bay Capital Management LP	added	27.39	18,234,500	62,769,800	0.25%
Dec 06, 2023	CITIGROUP INC	reduced	-13.16	-17,819,400	435,950,000	0.33%
Dec 06, 2023	Grant Street Asset Management, Inc.	reduced	-1.99	40,571	521,513	0.21%
Dec 06, 2023	Fragasso Group Inc.	added	1.5	198,082	1,810,150	0.19%
Dec 06, 2023	Raleigh Capital Management Inc.	added	0.06	237,057	2,450,950	1.30%
Dec 06, 2023	VisionPoint Advisory Group, LLC	added	2.13	164,954	1,434,520	0.62%
Dec 05, 2023	Advisory Resource Group	reduced	-10.26	-2,058	290,683	0.08%
Dec 05, 2023	Morton Capital Management LLC/CA	added	0.68	144,118	1,410,360	0.50%

Latest Funds Activity

Are funds buying ABBV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABBV

No. of Funds

Schedule 13G FIlings of AbbVie Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2023	blackrock inc.	7.8%	138,702,758	SC 13G/A
Feb 09, 2023	vanguard group inc	8.95%	158,317,552	SC 13G/A
Feb 09, 2022	vanguard group inc	8.28%	146,312,069	SC 13G/A
Feb 03, 2022	blackrock inc.	7.3%	128,197,555	SC 13G/A
Feb 16, 2021	capital research global investors	2.1%	37,921,062	SC 13G/A
Feb 10, 2021	vanguard group inc	8.08%	142,563,074	SC 13G/A
Jan 29, 2021	blackrock inc.	7.0%	124,423,484	SC 13G/A
Feb 14, 2020	capital research global investors	5.8%	86,602,693	SC 13G/A
Feb 12, 2020	vanguard group inc	8.28%	122,574,720	SC 13G/A
Feb 05, 2020	blackrock inc.	6.7%	98,593,810	SC 13G/A

Recent SEC filings of AbbVie Inc

View All Filings

Date Filed	Form Type	Document
Dec 06, 2023	8-K	Current Report
Nov 30, 2023	8-K	Current Report
Nov 15, 2023	25-NSE	25-NSE
Nov 06, 2023	10-Q	Quarterly Report
Oct 27, 2023	8-K	Current Report
Oct 19, 2023	3	Insider Trading
Oct 19, 2023	3	Insider Trading
Oct 12, 2023	8-K	Current Report
Oct 04, 2023	8-K	Current Report
Oct 03, 2023	4	Insider Trading

ABBV Fair Value

Peers (Alternatives to AbbVie Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	389.5B	102.8B	2.69%	-12.25%	11.25	3.79	11.47%	80.74%
MRK	272.8B	59.3B	-0.63%	-5.14%	17.88	4.63	0.58%	-69.80%
PFE	162.5B	68.5B	-6.62%	-44.42%	15.5	2.37	-31.38%	-64.79%
AMGN	144.0B	26.8B	-1.52%	-4.93%	19.03	5.37	1.91%	10.69%
GILD	98.5B	27.4B	1.44%	-10.10%	16.77	3.6	0.94%	76.21%
MID-CAP
TEVA	11.0B	15.3B	7.32%	18.03%	-4.98	0.72	0.87%	-71.24%
ALKS	4.3B	1.6B	4.36%	1.49%	20.08	2.71	40.56%	266.27%
PRGO	4.0B	4.7B	2.10%	-7.72%	-978.12	0.86	5.74%	96.18%
AMPH	2.7B	601.3M	24.99%	94.42%	20.1	4.52	24.02%	75.17%
BHC	2.7B	8.5B	1.81%	-4.07%	-2.77	0.31	5.11%	-479.13%
SMALL-CAP
TLRY	1.4B	650.9M	10.34%	-28.86%	-0.96	2.13	6.08%	-185.21%
TXMD	22.1M	-	-5.00%	-65.05%	0.32	0.55	-19.54%	888.31%
ACOR	15.2M	111.1M	27.41%	2089.90%	-0.96	0.14	-10.43%	84.90%
ACRX	12.5M	-	39.62%	-61.05%	-0.59	0.13	287.27%	-145.15%
AGRX	5.2M	20.0M	16.16%	1110.53%	-0.38	0.26	137.71%	66.04%

AbbVie Inc News

Latest updates

MarketBeat • 09 Dec 2023 • 08:39 am • 15 hours ago

AbbVie Inc. (NYSE:ABBV) Receives Consensus Recommendation ...

MarketBeat • 08 Dec 2023 • 08:15 pm • 27 hours ago

United Capital Financial Advisers LLC Trims Stock Position in ...

InvestorsObserver • 08 Dec 2023 • 05:41 pm • 30 hours ago

What is Wall Street's Target Price for AbbVie Inc (ABBV) Stock Friday?

Nasdaq • 08 Dec 2023 • 02:00 pm • 33 hours ago

Validea Detailed Fundamental Analysis - ABBV

Yahoo Finance • 07 Dec 2023 • 09:11 pm • 2 days ago

Top Stock Reports for AbbVie, NIKE & BHP

Investing.com UK • 07 Dec 2023 • 06:13 pm • 2 days ago

Why Methode Electronics Shares Are Trading Lower By Over 14 ...

Investing.com Australia • 07 Dec 2023 • 05:07 pm • 2 days ago

Midday movers: AMD, Alphabet, and more By Investing.com

AbbVie • 06 Dec 2023 • 09:31 pm • 3 days ago

AbbVie to Acquire Cerevel Therapeutics in Transformative ...

StreetInsider.com • 06 Dec 2023 • 04:54 pm • 3 days ago

Form 487 FT 11120

StockNews.com • 06 Dec 2023 • 03:54 pm • 3 days ago

ABBV: Analyzing December Profit Potential for the Top 4 Pharma ...

WTOP • 06 Dec 2023 • 08:00 am • 3 days ago

10 Best Investments for 2024

Yahoo Finance • 05 Dec 2023 • 02:00 pm • 4 days ago

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You ...

Yahoo Finance • 05 Dec 2023 • 04:00 am • 4 days ago

Here's Why AbbVie (ABBV) Rose in Q3

Bluefield Daily Telegraph • 04 Dec 2023 • 09:31 pm • 5 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors ...

MarketBeat • 04 Dec 2023 • 08:14 pm • 5 days ago

Lbp Am Sa Buys 35103 Shares of AbbVie Inc. (NYSE:ABBV)

Financials for AbbVie Inc

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	0.4%	13,927	13,865	12,225	15,121	14,812	14,583	13,538	14,886	14,342	13,959	13,010	13,858	12,902	10,425	8,619	8,704	8,479	8,255	7,828	8,305	8,236
Costs and Expenses	24.5%	11,646	9,352	9,457	9,619	10,209	11,288	8,821	9,812	10,036	9,518	8,907	10,105	9,647	9,673	5,016	4,748	5,862	4,855	4,818	10,746	5,077
S&GA Expenses	3.2%	3,372	3,268	3,039	3,417	3,304	5,412	3,127	3,260	3,083	3,164	2,842	3,231	2,846	3,527	1,695	1,951	1,657	1,654	1,680	1,929	1,919
EBITDA Margin	-20.5%	0.16*	0.20*	0.22*	0.29*	-	0.26*	0.31*	0.29*	-	-	0.14*	0.13*	0.24*	0.26*	0.32*	0.31*	0.13*	0.15*	-	-	-
Income Taxes	-70.5%	172	583	234	493	448	255	436	226	508	394	312	-1,545	187	46.00	88.00	273	117	66.00	88.00	-547	14.00
Earnings Before Taxes	-25.2%	1,953	2,610	475	2,965	4,400	1,183	4,929	4,271	3,688	1,163	3,867	-1,507	2,500	-693	3,098	3,074	2,001	807	2,544	-2,373	2,761
EBT Margin	-22.2%	0.15*	0.19*	0.16*	0.23*	0.26*	0.25*	0.25*	0.23*	0.13*	0.11*	0.08*	0.07*	0.20*	0.21*	0.26*	-	-	-	-	-	-
Net Income	-12.2%	1,778	2,024	239	2,473	3,949	924	4,490	4,044	3,179	766	3,553	36.00	2,308	-738	3,010	2,801	1,884	741	2,456	-1,826	2,747
Net Income Margin	-23.8%	0.12*	0.16*	0.13*	0.20*	0.23*	0.22*	0.22*	0.21*	0.14*	0.12*	0.10*	0.10*	0.18*	0.19*	0.25*	-	-	-	-	-	-
Free Cashflow	19.8%	7,355	6,141	4,018	7,215	7,425	4,862	4,746	4,888	7,718	4,695	4,689	4,575	5,613	2,912	3,690	-	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	0.6%	136,221	135,367	134,544	138,805	141,325	143,186	143,211	146,529	148,858	147,972	150,501	150,565	149,621	149,530	91,199	89,115	59,441	57,142	56,769	59,352	66,164
Current Assets	15.2%	33,224	28,852	26,488	28,463	30,364	29,100	26,509	27,928	28,957	25,999	26,569	24,173	23,009	21,256	51,758	49,519	20,166	15,100	14,413	16,945	18,465
Cash Equivalents	51.7%	13,287	8,759	6,711	9,201	11,832	8,521	6,098	9,746	12,182	8,546	9,755	8,449	7,890	6,017	41,142	39,924	10,648	5,172	4,897	7,289	8,015
Inventory	-1.8%	3,981	4,055	3,833	3,579	3,172	3,396	3,483	3,128	3,094	3,386	3,272	3,310	3,474	4,059	1,844	1,813	1,929	1,895	1,702	1,605	1,786
Net PPE	-0.2%	4,934	4,943	4,931	4,935	4,893	4,958	5,075	5,110	5,130	5,161	5,193	5,248	4,986	4,908	2,961	2,962	2,894	2,879	2,860	2,883	2,950
Goodwill	-0.4%	32,091	32,224	32,220	32,156	31,726	32,028	32,298	32,379	32,296	32,398	32,349	33,124	42,801	42,669	15,561	15,604	15,537	15,642	15,606	15,663	15,718
Current Liabilities	7.9%	34,773	32,239	27,590	29,538	32,712	34,473	32,521	35,194	28,533	28,684	31,951	28,661	24,181	24,646	16,471	15,585	17,493	16,941	13,904	17,239	15,387
Short Term Borrowings	-	2.00	-	1.00	1.00	10.00	17.00	12.00	14.00	16.00	17.00	9.00	34.00	54.00	64.00	6.00	-	-	306	499	3,699	3,002
Long Term Debt	-0.3%	55,631	55,812	59,292	59,135	60,399	61,002	63,522	64,189	74,049	74,237	74,183	77,554	82,282	82,061	63,284	62,975	33,126	31,619	35,066	35,002	36,487
Shareholder's Equity	-5.7%	12,129	12,866	13,303	17,254	15,994	14,688	16,314	15,436	13,577	12,594	13,733	13,097	15,289	14,732	-	-	-	-	-	-	-
Retained Earnings	-47.8%	933	1,789	2,393	4,784	4,953	3,516	5,103	3,127	1,600	740	2,292	1,055	3,335	3,130	5,973	4,717	3,673	3,384	4,234	3,368	6,789
Additional Paid-In Capital	0.9%	20,021	19,839	19,619	19,245	19,056	18,906	18,731	18,305	18,108	17,936	17,712	17,384	17,148	16,953	15,401	15,193	15,112	15,028	14,940	14,756	14,680
Shares Outstanding	-100.0%	-	1,767	1,770	-	1,771	1,770	1,771	-	1,770	1,769	1,769	-	1,769	1,647	1,481	-	1,481	1,480	1,480	-	1,511
Minority Interest	9.4%	35.00	32.00	29.00	33.00	33.00	35.00	31.00	28.00	27.00	25.00	23.00	21.00	19.00	24.00	-	-	-	-	-	-	-

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	19.9%	7,574	6,319	4,193	7,428	7,602	5,005	4,908	5,075	7,935	4,890	4,877	4,854	5,830	3,089	3,815	3,275	4,555	2,477	3,017	3,392	4,524
Share Based Compensation	-27.4%	130	179	313	132	126	107	306	129	135	159	269	136	162	236	219	79.00	75.00	87.00	189	70.00	75.00
Cashflow From Investing	-8.2%	-369	-341	-499	-448	1,286	130	-1,591	-1,145	-615	-242	-342	-627	-1,149	-35,652	-129	-615	1,378	-140	-27.00	-283	-963
Cashflow From Financing	32.1%	-2,661	-3,920	-6,192	-9,634	-5,518	-2,679	-6,972	-6,338	-3,643	-5,884	-3,174	-3,695	-2,814	-2,570	-2,422	26,602	-441	-2,070	-5,383	-3,825	916
Dividend Payments	0.1%	2,627	2,625	2,661	2,506	2,504	2,507	2,526	2,314	2,315	2,310	2,322	2,101	2,100	1,752	1,763	1,595	1,591	1,592	1,588	1,451	1,461
Buy Backs	-60.0%	4.00	10.00	1,955	4.00	4.00	9.00	1,470	131	6.00	10.00	787	296	20.00	19.00	643	2.00	4.00	3.00	620	2,058	1,009

ABBV Income Statement

2023-09-30

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net revenues	$ 13,927	$ 14,812	$ 40,017	$ 42,933
Cost of products sold	6,485	5,022	14,711	13,244
Selling, general and administrative	3,372	3,304	9,679	11,843
Research and development	1,723	1,614	5,748	4,720
Acquired IPR&D and milestones	66	40	496	454
Other operating expense (income), net	0	229	(179)	57
Total operating costs and expenses	11,646	10,209	30,455	30,318
Operating earnings	2,281	4,603	9,562	12,615
Interest expense, net	398	497	1,306	1,568
Net foreign exchange loss	25	36	97	108
Other expense (income), net	(95)	(330)	3,121	427
Earnings before income tax expense	1,953	4,400	5,038	10,512
Income tax expense	172	448	989	1,139
Net earnings	1,781	3,952	4,049	9,373
Net earnings attributable to noncontrolling interest	3	3	8	10
Net earnings attributable to AbbVie Inc.	$ 1,778	$ 3,949	$ 4,041	$ 9,363
Per share data
Basic earnings per share (in dollars per share)	$ 1.00	$ 2.22	$ 2.27	$ 5.26
Diluted earnings per share (in dollars per share)	$ 1.00	$ 2.21	$ 2.26	$ 5.24
Weighted-average basic shares outstanding (in shares)	1,767	1,771	1,768	1,771
Weighted-average diluted shares outstanding (in shares)	1,771	1,776	1,772	1,777

ABBV Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and equivalents	$ 13,287	$ 9,201
Short-term investments	3	28
Accounts receivable, net	11,412	11,254
Inventories	3,981	3,579
Prepaid expenses and other	4,541	4,401
Total current assets	33,224	28,463
Investments	275	241
Property and equipment, net	4,934	4,935
Intangible assets, net	58,603	67,439
Goodwill	32,091	32,156
Other assets	7,094	5,571
Total assets	136,221	138,805
Current liabilities
Short-term borrowings	2	1
Current portion of long-term debt and finance lease obligations	5,113	4,135
Accounts payable and accrued liabilities	29,658	25,402
Total current liabilities	34,773	29,538
Long-term debt and finance lease obligations	55,631	59,135
Deferred income taxes	2,044	2,190
Other long-term liabilities	31,644	30,655
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,822,577,212 shares issued as of September 30, 2023 and 1,813,770,294 as of December 31, 2022	18	18
Common stock held in treasury, at cost, 57,091,177 shares as of September 30, 2023 and 44,589,000 as of December 31, 2022	(6,525)	(4,594)
Additional paid-in capital	20,021	19,245
Retained earnings	933	4,784
Accumulated other comprehensive loss	(2,353)	(2,199)
Total stockholders' equity	12,094	17,254
Noncontrolling interest	35	33
Total equity	12,129	17,287
Total liabilities and equity	$ 136,221	$ 138,805

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal BehÃƒÂ§et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

CEO	Mr. Richard A. Gonzalez
WEBSITE	www.abbvie.com
EMPLOYEES	50000

AbbVie Inc Frequently Asked Questions

What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbbVie Inc (ABBV)?

As of Fri Dec 08 2023, market cap of AbbVie Inc is 263.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart. The fair value of AbbVie Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbbVie Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABBV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbbVie Inc a good stock to buy?

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, ABBV's PE ratio (Price to Earnings) is 40.48 and Price to Sales (PS) ratio is 4.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AbbVie Inc's stock?

In the past 10 years, AbbVie Inc has provided 0.153 (multiply by 100 for percentage) rate of return.

Market Summary

ABBV Alerts

ABBV Stock Price

ABBV RSI Chart

ABBV Alerts

ABBV Valuation

ABBV Price/Sales (Trailing)

ABBV Profitability

ABBV Fundamentals

ABBV Revenue

ABBV Earnings

Price Action

How does ABBV drawdown profile look like?

ABBV Financial Health

ABBV Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for ABBV

Which funds bought or sold ABBV recently?

Latest Funds Activity

Schedule 13G FIlings of AbbVie Inc

Recent SEC filings of AbbVie Inc

ABBV Fair Value

Peers (Alternatives to AbbVie Inc)

AbbVie Inc News

Financials for AbbVie Inc

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

ABBV Income Statement

ABBV Balance Sheet

About AbbVie Inc

AbbVie Inc Frequently Asked Questions

What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

What is the market capital of AbbVie Inc (ABBV)?

What is the fair value of ABBV stock?

Is AbbVie Inc a good stock to buy?

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on AbbVie Inc's stock?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)